## **Targeting FRα: Clinical Data**

#### Prof. Dr. T. Van Gorp

Div. Gynaecological Oncology Leuven Cancer Institute University Hospital Leuven, Belgium





## Disclosures

All payments institutional

#### Consulting/Advising

 AbbVie, AstraZeneca, BioNTech, Cancer Communications and Consultancy Ltd, Daiichi Sankyo, Eisai, GSK, ImmunoGen, Incyte, Karyopharm, MSD/Merck, OncXerna Therapeutics, Seagen, Tubulis, Zentalis

#### Honoraria for lectures


AbbVie, AstraZeneca, Eisai, GSK, ImmunoGen, MSD

#### Travel, accommodations, and/or expenses

- AstraZeneca, GSK, ImmunoGen, MSD, and PharmaMar
- Research funding

**KU LEUVEN** 

- Amgen, AstraZeneca, and Roche
- Leadership in a society, committee or advocacy group, paid or unpaid
  - Chair of the Belgian and Luxembourg Gynaecological Oncology Group (BGOG) (unremunerated)





#### **Multiple ADCs targeting FRα are under development**


Example ADCs under development		Linker	Payload	ΜΟΑ	Stage of development	Clinicaltrials. gov
	AZD5335	Undisclosed	AZ14170132	TOP1i	Phase 1/2	NCT05797168
Farletuzumab ecteribulin	MORAb-202	Cleavable	Eribulin	MTi	Phase 1/2	NCT04300556
	IMGN151	Cleavable	DM21	MTi	Phase 1	NCT05527184
Luveltamab tazevibulin	STRO-002	Cleavable	Hemiasterlin	MTi	Phase 2/3 ongoing	NCT05870748
Mirvetuximab soravtansine	Mirv; IMGN853	Cleavable	DM4	MTi	Phase 3 complete	NCT04209855
Rinatabart sesutecan	Rina-S; PRO1184	Cleavable	Exatecan	TOP1i	Phase 1/2 ongoing	NCT05579366



#### **Mirvetuximab-soravtansine (Mirv)**



anti-Folate R1 mirvetuximab soravtansine






## SORAYA study: design




A phase II single arm trial with Mirvetuximab soravtansine





Matulonis et al. SGO 2022 Matulonis et al. J Clin Oncol 41:2436-2445

## **Objective Response Rate (Inv)**




#### 34 responders

- 5 complete responses
- 29 partial responses



**S**<sup>\*</sup> RAYA








Matulonis et al. SGO 2022 Matulonis et al. J Clin Oncol 41:2436-2445

## **Overall Survival**





Final Overall Survival<sup>\*</sup> in INV Efficacy Evaluable Population

Number of Patients at Risk

MIRV 105 104 103 97 91 83 77 73 68 65 64 63 57 57 52 48 46 45 36 27 21 12 9 6 5 2 0





14 Nov 2022


FDA grants <u>accelerated approval</u> to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer



#### **ENGOT-ov55/MIRASOL**



Phase 3 registration trial for Mirvetuximab Soravtansine in FRα High Patients



"BICR: Blinded Independent Central Review (PLD: pegylated liposomal doxorubicin



## **Baseline characteristics**



Characteristics	MIRV (n = 227)	IC Chemotherapy (n = 226)	Characteristics, continued.	MIRV (n = 227)	IC Chemotherapy (n = 226)	
Age Median (range), yr	64 (32-88)	62 (29-87)	Previous lines of systemic therapy, n (%) 1 2	29 (12.8) 90 (39.6)	34 (15.0) 88 (38.9)	
Primary cancer diagnosis, no. (%) Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer Other	182 (80.2) 27 (11.9) 16 (7.0) 2 (0.9)	182 (80.5) 23 (10.2) 20 (8.8) 1 (0.4)	3 <b>Previous exposure, n (%)</b> Bevacizumab PARP inhibitor	108 (47.6) 138 (60.8) 124 (54.6)	104 (46.0) 143 (63.3) 127 (56.2)	
Stage at initial diagnosis, n (%) <sup>a</sup>	7 (3.1)	1 (0.4)	Taxane Doxorubicin or PLD Topotecan	227 (100) 130 (57.3) 1 (0.4)	224 (99.1) 133 (58.8) 2 (0.9)	
IIB or IIC IIIA IIIB IIIC	2 (0.9) 14 (6.2) 16 (7.0) 107 (47.1)	8 (3.5) 16 (7.1) 11 (4.9)	) 16 (7.1) ) 11 (4.9)	Primary platinum-free interval, n (%) <sup>b</sup> ≤12 months >12 months	146 (64.3) 80 (35.2)	142 (62.8) 84 (37.2)
IV	76 (33.5)	65 (28.8)	Platinum-free interval, n (%) <sup>c</sup> <3 months	88 (38.8)	99 (43.8)	
BRCA mutation, n (%) BRCA1 positive BRCA2 positive Negative or unknown	24 (10.6) 9 (4.0) 198 (87.2)	29 (12.8) 7 (3.1) 190 (84.1)	>3 to ≤6 months >6 months	138 (60.8) 1 (0.4)	124 (54.9) 3 (1.3)	


Tables adapted from Moore KN, et al.<sup>1</sup> Data cutoff: March 6, 2023. 14% of patients remain on MIRV; 3% remain on IC Chemotherapy at data-cut off.

<sup>a</sup>Five patients (2%) in the MIRV arm and five patients in the IC chemotherapy arm (2%) were missing information for stage at initial diagnosis. <sup>b</sup>One patient (<1%) in the MIRV arm was missing information on primary platinum-free interval. <sup>c</sup>One patient (<1%) in the MIRV arm and 3 patients (1%) in the IC chemotherapy arm enrolled with platinum-free interval of >6 months.

BRCA, BReast CAncer gene; IC, investigator's choice; MIRV, mirvetuximab soravtansine; PARPi, poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitor; PLD, pegylated liposomal doxorubicin.









## **ORR (INV)**




	MIRV (n=227)	IC Chemo (n=226)		
ORR	<b>42%</b>	16%		
n, 95% Cl	96, (5.8, 49.0)	36, (11.4, 21.4)		
Best overall response, n (%)				
CR	12 ( <mark>5%</mark> )	0		
PR	84 (37%)	36 (16%)		
<b>SD</b> 86 (38%) 91 (40%)				
PD 31 (14%) 62 (27%)				
Not evaluable         14 (6%)         37 (16%)				
ORR Difference 26.4% (18.4, 34.4) OR 3.81 (2.44, 5.94) <i>p</i> <0.0001				

Data cutoff: March 6, 2023. MIRV, mirvetuximab soravtansine; IC chemo, investigator's choice chemotherapy; ORR, objective response rate; CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; OR, odds ratio.



#### Change in target lesion size from baseline MIRAS<sup>\*\*</sup>L



Data cutoff: March 6, 2023 MIRV, mirvetuximab soravtansine; IC chemo, investigator's choice chemotherapy; ORR, objective response rate.

**MIRV** 




ClinicalTrials.gov identifier: NCT04209855 Moore KN et al. ASCO 2023 Moore KN et al. N Engl J Med. 2023;389(23):2162-2174

**IC Chemo** 

## **Overall Survival**







## PFS/OS according to prior Bevacizumab use (Inv)

	Bev-Naïve		Prior Bev		
	MIRV IC Chemo		MIRV	IC Chemo	
mPFS (95% CI)	7.0 (5.6, 8.4)	5.6 (3.0, 6.5)	4.4 (4.0, 5.8)	3.0 (2.5, 4.3)	
Events n (%) <sup>a</sup>	65 (73.0)	57 (69.0)	111 (80.4)	109 (76.2)	
HR (95% CI)	0.66 (0.46, 0.94)		0.64 (0.49, 0.84)		
Nominal <i>p</i> -value	0.0	0.0210		0.0011	
mOS (95% CI)	20.2 (14.8, NE)	14.4 (11.8, 16.7)	15.4 (11.3, 17.5)	10.9 (9.4, 13.3)	
Events n (%) <sup>a</sup>	23 (25.8)	39 (47.0)	67 (48.6)	75 (52.4)	
HR (95% CI)	0.51 (0.31, 0.86)		0.74 (0.54, 1.04)		
Nominal <i>p</i> -value	0.0099		0.0789		

Data cutoff: March 6, 2023

<sup>a</sup>Percentage of events was calculated out of the total number of patients in each treatment arm: n=227 for MIRV and n=226 for IC Chemo.

mPFS, median progression-free survival; HR, hazard ratio; CI, confidence interval; mOS, median overall survival; MIRV, mirvetuximab soravtansine; Bev, bevacizumab; IC Chemo, investigator's choice chemotherapy.







See next presentation



#### **Summary**



- Compared to IC chemo, MIRV demonstrated:
  - **35% improvement in PFS:** HR of 0.65, *p*<0.0001
  - o 26% increase of the ORR: 42% vs 16%, p<0.0001</p>
  - **33% improvement in OS:** HR of 0.67, *p*=0.0046
- Both BEV-naïve and BEV-pretreated subgroups demonstrated a consistent benefit with MIRV
- These data are practice-changing and position MIRV as a **new standard of care** for patients with FR $\alpha$ -positive PROC



## FDA and now also EMA approval!

## **DA** U.S. FOOD & DRUG

#### 14 Nov 2022

FDA grants <u>accelerated approval</u> to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer

22 Mar 2024

I FUVEN

FDA <u>approves</u> mirvetuximab soravtansinegynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer


EUROPEAN MEDICINES AGENCY Science medicines health

#### 18 Nov 2024


#### November 18, 2024

AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE



# Using the correct test & interpretation is essential










## **Characterization of FRα expression**

#### Representative low, medium, and high staining patterns for FRα from archival tumour specimens








Low 25–49% of cells with ≥2+ intensity Medium 50–74% of cells with ≥2+ intensity High ≥75% of cells with ≥2+ intensity

## **Characterization of FRα expression**

LEUVEN



Deutschman E, et al. 36th European Congress of Pathology (ECP). 2024; Abs 2093 and poster.

## **FORWARD**

- Platinum-resistant ovarian cancer
- FRa-positive tumor expression
  - Medium (50-74% cells positive)
  - High (≥75% cells positive)
- ECOG performance status 0 or 1
- 1-3 prior therapies

#### **Statistical Assumptions**

- Hochberg procedure
- α=0.05 (two-sided), power = 90%
   HR=0.58; control arm mPFS 3.5 mos

Mirvetuximab Soravtansine (n=248)

6 mg/kg (adjusted ideal body weight) Q3W

#### 2:1 Randomization

#### Stratification Factors:

- FRa expression (medium or high)
- Prior therapies (1 and 2, or 3)
- Choice of chemotherapy

Investigator's Choice Chemotherapy Paclitaxel, PLD<sup>+</sup>, or Topotecan (n=118)

Paclitaxel: 80 mg/m<sup>2</sup> weekly PLD: 40 mg/m<sup>2</sup> once every 4 weeks Topotecan: 4 mg/m<sup>2</sup> on Days 1, 8, and 15 Q4W; or 1.25 mg/m<sup>2</sup> on Days 1-5 Q3W

#### Primary Endpoint

#### PFS by BIRC\* for ITT and high FRα populations


\*BIRC = Blinded Independent Review Committee; analyzed by Hochberg procedure

#### Secondary Endpoints

Overall response rate (ORR) Overall survival (OS) Patient reported outcomes (PRO)

#### **Primary endpoint: PFS (BICR)**






\*not significant per Hochberg procedure Moore et al. ESMO 2019 ClinicalTrials.gov Identifier: NCT02631876




#### $FR\alpha$ scoring in the mirvetuximab soravtansine program

#### **PS2+** Scoring

- In all prior studies, PS2+ scoring was used to assess FRa expression
- Eligibility determined by staining intensity and percentage of tumor cells staining at 0, 1+, 2+, or 3+






#### **10X Scoring**

- In FORWARD I, a simplified scoring method to assess FRa expression was implemented
- Eligibility was determined by scoring just the percentage of cells with membrane staining by <10X magnification, without regard to intensity

#### **10X Scoring** Positive: ≥ 50% of tumor cells with FRα membrane staining visible at 10X microscope objective




Bridging study indicated that 10X scoring was sufficient for patient selection Exploratory analyses suggest that the change in scoring method from PS2+ to 10X introduced a population of patients into FORWARD I with lower levels of FRα expression than intended





Rescoring of the FORWARD I samples using PS2+ indicates:

- 34% of patients enrolled in FORWARD I had low FRα levels that should have precluded enrollment; and
- the protocol-defined FRα high subset contained patients with a mixture of FRα expression levels






#### **PS2+ re-scoring: PFS trends**



**PFS Hazard Ratio Plot** 

PFS (by BIRC) - FRα High (n=116)




P values from unstratified log-rank test



Moore et al. ESMO 2019 ClinicalTrials.gov Identifier: NCT02631876

#### **PS2+ re-scoring: OS in FR** $\alpha$ **HIGH**








## VENTANA FOLR1 (FOLR1-2.1) RxDx Assay

Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE



Precision	Agreement				
Precision	Туре	n/N	%	95% CI	
	APA	286/295	96.9	(95.1, 98.6)	
Within-Reader	ANA	296/305	97.0	(95.1, 98.7)	
	OPA	291/300	97.0	(95.0, 98.7)	
	APA	276/296	93.2	(89.4, 96.8)	
Between-Reader	ANA	284/304	93.4	(89.9, 96.8)	
	OPA	280/300	93.3	(90.0, 96.7)	

 Table 11.
 Within-Reader and Between- Reader and Precision of VENTANA FOLR1 (FOLR1-2.1) RxDx Assay of EOC specimens.


Note: Average Positive Agreement (APA), Average Negative Agreement (ANA),

 Overall Percent Agreement (OPA).

VENTANA FOLR1 (FOLR1-2.1) RxDx Assay insert https://www.accessdata.fda.gov/cdrh\_docs/pdf22/P220006C.pdf

#### But!

• FRα in Patient-Matched Primary vs Metastatic Lesions




Matched Sample Summary		Correlation	
Cases with Matched Omental and Adnexal Tumor	59 Coefficient		
Average Omental FOLR1 PS2+ Score	50.6	0.65	
Average Adnexal FOLR1 PS2+ Score			
		n/N (%)	
Cases with Concordant Results		46/59 (78)	
Cases with Discordant Results		13/59 (22)	
Positive to Negative		0/59 (17)	
Negative to Positive		3/59 (5)	



#### But!

FOLR1 PS2 Per Core (%) FRα variation among specimens within the same biopsy



**PS2 Scores for Individual Cases** 

FOLR1 PS2 Spread Per Case ( ) = adnexa | ) = omentum | ) = other site). Bubble area represents frequency of identical scores

Core FOLR1 Result	Primary Tumor n (%)	Metastatic Tumor n (%)
Mixed	20 (27)	20 (34)
All Positive	16 (22) 73%	7 (12) 660/
All Negative	38 (51) 7 3 %	31 (53) 66%



Deutschman E, et al. 36th European Congress of Pathology (ECP). 2024; Abs 2093 and poster.

## What is next?

CGOG UZ LEUVEN KU LEUVEN BGOB ENGOT 1. Views and experience of Prof. Dr. Philipp Harter, Evangelische Kliniken Essen-Mitte, Essen, Germany.

ImmunoGen is now part of AbbVie



## What is next?

• Platinum resistant disease

Combination with bevacizumab?

- Platinum sensitive disease
  - Monotherapy (platinum free regimen)?
  - Combination with carboplatinum?
  - Maintenance?



## What is next?

• Platinum resistant disease


Combination with bevacizumab?

- Platinum sensitive disease
  - Monotherapy (platinum free regimen)?
  - Combination with carboplatinum?
  - Maintenance?



### **FORWARD II**


Phase 2: MIRV in combination with bevacizumab in platinum agnostic OC





### **FORWARD II**

Confirmed ORR by FRα Expression and Platinum Status



ENGOT European Network of

UZ LEUVEN

**KU LEUVEN** 

- **50% ORR** (30/60) for overall cohort
- 64% ORR (21/33) in high FRα tumors
   59% ORR (10/17) in PROC subset
  - > 69% ORR (11/16) in PSOC subset


### **FORWARD II**

• Results: longer PFS in High FRα tumors

ENG OT

BGOG

**KU LEUVEN** 



## What is next?

• Platinum resistant disease

• Combination with bevacizumab?

- Platinum sensitive disease
  - Monotherapy (platinum free regimen)?
  - Combination with carboplatinum?
  - Maintenance?



### PICCOLO

## A single-arm, open-label, phase 2 trial of MIRV in patients with $\geq$ 3L platinum-sensitive ovarian cancer with FR $\alpha$ -high expression

#### **PICCOLO** Patient Population


#### **Enrollment and Key Eligibility**

- Platinum-sensitive disease (defined as radiographic progression >6 months from last dose of most recent platinum therapy)
- FRα high, detected by IHC with PS2+ intensity among ≥75% of viable tumor cells<sup>a</sup>
- At least 2 prior platinum-containing regimens<sup>b</sup>
- Prior PARPi required if BRCA+
- Prior BEV not required

**KU LEUVEN** 

LEUVEN

Appropriate for single-agent therapy




### **Baseline Demographics and Characteristics**

Characteristics	N=79
Age, median (range), years	66 (41-84)
Race, n (%)	
White	65 (82.3)
Black or African American	4 (5.1)
Asian	1 (1.3)
Not reported	8 (10.1)
Other	1 (1.3)
Number of prior lines of systemic therapy, n (%)	
1-2	49 (62.0)
≥3	30 (37.9)
Prior exposure to taxanes, n (%)	
Yes	77 (97.5)
Exposed in multiple lines	20 (25.3)
Νο	2 (2.5)

Characteristics	N=79
Prior exposure to PARPi,n (%)	
Yes	64 (81.0)
Progression	59 (74.7)
No progression	5 (6.3)
No	12 (15.2)
Prior exposure to bevacizumab, n (%)	
Yes	51 (64.6)
No	28 (35.4)
Platinum-free interval (months), n (%)	
≤12	43 (54.4)
>12	34 (43.0)

Of the 302 patients screened, 124 (44%) had ≥75% ≥2+ FRα tumor expression


### **Investigator-Assessed Efficacy Measures**



Primary Endpoint	N=79
<b>ORR, n (%)</b> (95% Cl)	41 ( <b>51.9</b> ) 40.4-63.3
Best overall response, n (%)	
CR	6 (7.6)
PR	35 (44.3)
SD	29 (36.7)
PD	7 (8.9)
Not evaluable	2 (2.5)

Secondary Endpoints	
Median DOR: months	8.25
(95% CI)	(5.55-10.78)
Median PFS: months	6.93
(95% CI)	(5.85-9.59)

### **ORR by Subgroups**



## What is next?


• Platinum resistant disease

Combination with bevacizumab?

- Platinum sensitive disease
  - Monotherapy (platinum free regimen)?
  - Combination with carboplatinum?
  - Maintenance?



### AGO-OVAR 2.34 (MIROVA): Study design





FRα, folate receptor alpha; PLD, pegylated liposomal doxorubicin; PS2+, positive staining intensity ≥2; TFI-p, platinum therapy-free interval. 1. NCT04274426. Accessed on 6.4.2024 from https://www.clinicaltrials.gov/study/NCT04274426. 2. Trillsch F, et al. European Society of Gynaecological Oncology (ESGO) Congress. 2022; Abs 2022-RA-835-ESGO and poster presentation.

### What is next?

• Platinum resistant disease

Combination with bevacizumab?

- Platinum sensitive disease
  - Monotherapy (platinum free regimen)?
  - Combination with carboplatinum?
  - Maintenance?



## What is next?

• Platinum resistant disease

Combination with bevacizumab?

### • Platinum sensitive disease

- Monotherapy (platinum free regimen)?
- Combination with carboplatinum?
- Maintenance?





### **GLORIOSA**

MIRV + Beva maintenance in FR $\alpha$ -high, platinum-sensitive disease

#### **Eligible patients**

- High-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer
- Relapsed after 1L platinum-based chemo
  - Platinum-sensitive disease (PFI >6 months)
  - 1L PARPi maintenance required if BRCAm
- Appropriate for, currently receiving, or completed 2L platinum-based triplet therapy
  - CR, PR, or SD after 2L platinum-based triplet, which included ≥3 cycles of bevacizumab
  - Randomized ≤8 weeks from the last dose of 2L platinum-based triplet therapy
- FRα-high by IHC with PS2+ intensity in ≥75% of viable tumour cells







### Conclusions

 Mirvetuximab soravtansine has shown an PFS and OS benefit in platinum-resistant ovarian cancer

• Multiple further trials with drugs targeting FRα are ongoing or under development

- Areas of interest:
  - Efficacy in a broader patient population regarding FRα status
  - Efficacy in earlier lines of therapy



# Questions?



### Targeting FRα: Management of Adverse Events

### Prof. Dr. T. Van Gorp

Div. Gynaecological Oncology Leuven Cancer Institute University Hospital Leuven, Belgium





### Disclosures

All payments institutional

#### Consulting/Advising

 AbbVie, AstraZeneca, BioNTech, Cancer Communications and Consultancy Ltd, Daiichi Sankyo, Eisai, GSK, ImmunoGen, Incyte, Karyopharm, MSD/Merck, OncXerna Therapeutics, Seagen, Tubulis, Zentalis

#### Honoraria for lectures

AbbVie, AstraZeneca, Eisai, GSK, ImmunoGen, MSD

#### Travel, accommodations, and/or expenses

- AstraZeneca, GSK, ImmunoGen, MSD, and PharmaMar
- Research funding


**KU LEUVEN** 

- Amgen, AstraZeneca, and Roche
- Leadership in a society, committee or advocacy group, paid or unpaid
  - Chair of the Belgian and Luxembourg Gynaecological Oncology Group (BGOG) (unremunerated)

### ENGOT-ov55/MIRASOL



Phase 3 registration trial for Mirvetuximab Soravtansine in FRα High Patients



"BICR: Blinded Independent Central Review (PLD: pegylated liposomal doxorubicin






	MIRV (n=218)	IC Chemo (n=207)
Any TEAE, n (%)	210 (96)	194 (94)
Grade 3+ TEAEs, n (%)	91 ( <b>42</b> )	112 <b>(54)</b>
SAEs, n (%)	52 ( <b>24</b> )	68 ( <b>33</b> )
Deaths on study drug or <30 days of last dose, n (%)	5 (2)	5 (2)
Dose reductions due to TEAEs, n (%)	74 (34)	50 (24)
Dose delays due to TEAEs, n (%)	117 (54)	111 (54)
Discontinuations due to TEAEs, n (%)	20 ( <b>9</b> )	33 ( <b>16</b> )

Data cutoff: March 6, 2023. The safety population comprises all patients who received at least one dose of MIRV or IC Chemo. TEAEs, treatmentemergent adverse events; SAEs, serious adverse events; MIRV, mirvetuximab soravtansine; IC, investigator's choice chemotherapy.



### **Treatment-Emergent Adverse Events**






ClinicalTrials.gov identifier: NCT04209855 Moore KN et al. ASCO 2023 Moore KN et al. N Engl J Med. 2023;389(23):2162-2174

MIRAS

### Hematologic

UZ LEUVEN



BGOG

**KU LEUVEN** 

- Off-target cytotoxic damage into hematopoietic stem cells of the bone marrow
- Incidence < 12%
- Mostly Grade 1-2

ClinicalTrials.gov identifier: NCT04209855 Moore KN et al. ASCO 2023 Moore KN et al. N Engl J Med. 2023;389(23):2162-2174

### Hematologic


### **Dose modifications**

- Criteria to receive Mirv:
  - ANC  $\geq$  1.5x10<sup>9</sup>/L
  - Plat. count  $\ge$  80 x 10<sup>9</sup>/L

Severity Grade (CTCAE v4.03)	Dose Modifications for IMGN853	
Hematological		
Neutropenia		
Grade 2 and Grade 3	Hold drug until ANC is $\geq 1.5 \times 10^9$ /L (1500 /µL) and resume at the same dose level	
Grade 4	Hold drug until ANC is $\geq 1.5 \times 10^9/L (1500 / \mu L)$ and then resume at a lower dose level	
Febrile neutropenia Grade 3 or 4 (with a single temperature reading $\geq$ 38.3°C or a sustained temperature of $>$ 38°C for $>$ one hour )	Hold drug until ANC is $\geq 1.5 \times 10^9$ /L (1500 /µL) and then resume at a lower dose level	
Thrombocytopenia		
Grade 2 and Grade 3	Hold drug until Platelet count is $\geq 80 \ge 10^9/L$ (80,000/µL) and resume at same dose level	
Grade 3 associated with clinically significant bleeding that requires transfusion therapy and Grade 4	Hold drug until Platelet count is $\ge 80 \ge 10^9/L$ (80,000/µL) and then resume at a lower level	




## Peripheral neuropathy and alopecia



LGOG

- Peripheral neuropathy
  - Off-target: Non-specific uptake of ADC in peripheral nerves and release of payload.
    AE of all microtubule inhibitors such DM1, DM4, MMAE, and MMAF
  - Mirv 22 % ↔ Pac 29%
    - Mostly Grade 1-2
    - G3+: Mirv only 1% ↔ Pac 5%
  - Dose reduction was considered in the case of G2 interfering patient's normal life
- Almost no <u>alopocia</u>!

### **Gastro-intestinal**



- Off-target effect


   standard chemo
- Incidence 27-29 %
- Mostly Grade 1-2 (only 1-2% G3+)
- In the case of G3 despite optimal use of anti-emetic or anti-diarrheal treatment: Drug was held until resolution to < G1, then resumed at a lower level

ClinicalTrials.gov identifier: NCT04209855 Moore KN et al. ASCO 2023 Moore KN et al. N Engl J Med. 2023;389(23):2162-2174



LGOG


**KU LEUVEN** 




- Off-target toxicity
  - There is no FR $\alpha$  expression in corneal 0 epithelial tissues
- Significant more frequent with MIRV compared to IC Chemo
- Among the most common AEs in pts treated w/ MIRV (59%)
- Predominantly G1-2

ClinicalTrials.gov identifier: NCT04209855 Moore KN et al. ASCO 2023 Moore KN et al. N Engl J Med. 2023;389(23):2162-2174









ClinicalTrials.gov identifier: NCT04209855 Moore KN et al. ASCO 2023 Moore KN et al. N Engl J Med. 2023;389(23):2162-2174 Matulonis et al. SGO 2022 Matulonis et al. J Clin Oncol 2023;41(13):2436-45











Pooled safety analysis of **4 clinical trials** which involved **682** patients with FRα positive rOC

	Integrated Safety Summary (N=682)
Participants with ocular AEs	N= 405
Action taken due to ocular AEs No dosing-related action taken Dose delayed/not given or interrupted Dose reduced Permanent discontinuation	221 (55%) 174 ( <b>43%</b> ) 105 ( <b>26%</b> ) 8 ( <b>2%</b> )




Mechanism








Mechanism







The limbus provides a reservoir of stem cells for the regeneration corneal epithelium.



Mechanism








- Mechanism
  - D Control




Mirvetuximab soravtansine



#### Deeper corneal layers are not affected (stroma, endothelial layer)

Matulonis et al. Clin Can Res 2019






#### Corneal microcysts


Flattening of the corneal surface curvature


**KU LEUVEN** 

V LGOG


BGOG







### **Ocular AE's when using ADCs in general**





### Ocular

- Evolution after Mirv treatment:
  - Regeneration of corneal epithelium, with eventual shedding of areas demonstrating epithelial damage
  - For all patients with complete follow-up data, ocular AEs resolved to grade 0/1
  - Single-agent MIRV administration did <u>not</u> result in any corneal ulcers or corneal perforations, and no patients had permanent ocular sequelae



#### Ocular

#### **Protocol management of ocular toxicity?**

- Prophylactic and mitigative measures
- Treatment and dose modification



#### Recommendations for Patients and Caregivers

#### Use recommended and prescribed eye drops

Use ophthalmic topical steroids by administering 1 drop in each eye 6x daily (starting the day prior to each infusion) until Day 4; then 1 drop in each eye 4x daily for Days 5-8 of each cycle of MIRV

Use preservative-free lubricating eye drops at least 4x daily, and as needed

- Wait at least 10 min after ophthalmic topical steroid administration before instilling lubricating eye drops

UZ LEUVEN

#### Implement best practices for eye health

Practice good eyelid margin hygiene (eg, clean around eyes, apply warm compresses)

Use sunglasses during full daylight

Avoid use of contact lenses during treatment (unless directed by an HCP)

Know the risks for dry eye disease (eg, extended screen use, certain medications, environmental factors)

#### Corticosteroid eye drops (1% prednisolone)

- Day -1 to 4: 6x/day
- Days 5 to 8: 1x/day
- Lubricating eye drops

**KU LEUVEN** 

• 4x/day throughout the cycle

#### Patient/Healthcare Team Collaboration

Proactively monitor ocular health and ensure prompt ophthalmic examination upon occurrence of ocular signs or symptoms

#### Oncologist and ECP Responsibilities

#### Ensure patients undergo baseline and routine ophthalmic examinations

Conduct an ophthalmic examination (including BCVA, slit lamp examination, and evaluation of intraocular pressure) prior to initiation of MIRV, every other cycle for the first 8 cycles, and as clinically indicated

 Corneal topography may be useful to further evaluate transient changes in refractive status associated with the presence of MECs

#### Implement prophylactic and mitigative steps for ocular events

Instruct patients on best eye health practices and the importance of monitoring for ocular symptoms

Ensure patients have access to the correct types of eye drops: preservative-free lubricating eye drops and ophthalmic topical steroids

 The initial prescription and renewals of any corticosteroid medication should be made only after examination with a slit lamp

Upon occurrence of any new or worsening ocular signs or symptoms, promptly refer patients to an ECP for ophthalmic examination

Withhold, reduce, or permanently discontinue MIRV based on severity and persistence of ocular events, using the recommendations in the MIRV PI

Summary of the Grad	ing of Key Ocular Adverse Even	ts in MIRV Clinical Trials (NCI CT	CAE v5.0, 2017 <b>).</b>		
CTCAE term	Grade 1	Grade 2	Grade 3	Grade 4	
Blurred vision <sup>a</sup>	Intervention not indicated	Symptomatic; moderate decrease in visual acuity; limiting instrumental ADL <sup>b</sup>	Symptomatic, with marked decrease in visual acuity; limiting self-care ADL <sup>c</sup>	Best corrected visual acuity of <b>20/200 or worse</b> in the affected eye	Protocol Recommende
Keratitis <sup>d</sup> (Included in keratopathy group term)	Asymptomatic; clinical or diagnostic observations only; intervention not indicated	Symptomatic; moderate decrease in visual acuity	Symptomatic, with marked decrease in visual acuity; corneal ulcer; limiting self-care ADL <sup>c</sup>	Perforation; best corrected visual acuity of <b>20/200 or</b> <b>worse</b> in the affected eye	Permanently discontinu
Dry eye <sup>e</sup>	Asymptomatic; clinical or diagnostic observations only; symptoms relieved by lubricants	Symptomatic; moderate decrease in visual acuity	Symptomatic, with marked decrease in visual acuity; limiting self-care ADL <sup>c</sup>		Protocol Recommended
Photophobia <sup>f</sup>	Symptomatic but not limiting ADL	Limiting instrumental ADL <sup>b</sup>	Limiting self-care ADL <sup>c</sup>		Withhold dose until improved or resolved,
		Definition: "Moderate decrease in visual acuity"	visual acuity"		then reduce by one dos level <sup>2</sup>
		Best corrected visual acuity $20/40$ and better or $\leq 3$ lines of decreased vision from known baseline	Best corrected visual acuity worse than 20/40 or >3 lines of decreased vision from known baseline, up to 20/200		

	P	rotocol Guidance For Management
	Severity (CTCAE Grade)	
_	Grade 1	<ul> <li>Complete eye exam</li> <li>Monitor for worsening symptoms</li> <li>No change in mirvetuximab soravtansine dose or schedule of administration</li> </ul>
	Grade 2	<ul> <li>Complete eye exam</li> <li>Weekly symptomatic ocular assessments until symptoms resolve or return to baseline</li> <li>Hold mirvetuximab soravtansine until improvement to Grade 1 or better</li> </ul>



### **Dose modifications**

#### Trial Protocol Recommended Starting Dose and Dose Modifications

Recommended dose reduction schedule for adverse events <sup>1</sup>			
	Dose Level		
Starting dose	6 mg/kg AIBW		
First dose reduction	5 mg/kg AIBW		
Second dose reduction	4 mg/kg AIBWª		

<sup>a</sup>Permanently discontinue in patients who cannot tolerate 4 mg/kg AIBW.

```
AIBW = IBW + 0.4(Actual weight in kg – IBW)
IBW (female) = 0.9(Height in centimeters) – 92
```



### **Interstitial Lung Disease (ILD) or Pneumonitis**

• Condidered as a 'Class effect' of ADCs

- Cause not clearly elucidated
  - We presume mainly off-target
- Evaluate immediately in case of shortness of breath, cough or respiratory distress



### **Interstitial Lung Disease (ILD) or Pneumonitis**


	All grades (%)	Grade 1-2 (%)	Grade ≥3 (%)	Reference
FORWARD I	2.9	2.9	0	Matulonis et al. J Clin Oncol 2023;41:2436
FORWARD II	6.7	6.7	0	Gilbert L et al. ASCO 2020
SORAYA	10.4	8.5	1.9	Matulonis et al. SGO 2022 Matulonis et al. J Clin Oncol 41:2436-2445
MIRASOL	?	?	?	Moore KN et al. NEJM 2023;389(23):2162 Moore KN e al. ASCO 2023
PICCOLO	10.1	6.3	3.7*	Secord et al. ESMO 2024
All	2.9 - 10.4	2.9 – 8.5	0-3.7	

\* 1 death reported



## **ILD/Pneumonitis**

Management



#### **ILD/Pneumonitis**


Guidelines for Dose Modifications	Medical Management of Pneumonitis	CTCAE v4.03 Grade
<ul> <li>• Continue dosing after discussion with the Sponsor.</li> </ul>	<ul> <li>Radiologic assessments (CT scan and/or chest x-ray) should be performed as clinically indicated.</li> <li>Monitor for pulmonary symptoms.</li> </ul>	Grade 1
resolve to ≤ Grade 1. Iist. • MIRV may be resumed at same dose level after discussion with the Sponse	<ul> <li>Radiologic assessments (CT scan and/or chest x-ray) should be performed as clinically indicated.</li> <li>Patient must be evaluated by a pulmonary specialist.</li> <li>Treatment with corticosteroids may be indicated</li> </ul>	Grade 2
<ul> <li>Hold Be careful, consider to reduct resolve to ≤ Grade 1.</li> <li>MIRV may be resumed at a lower dose level after discussion with the Sponsor.</li> <li>Be careful, consider to discontinue</li> </ul>	<ul> <li>Same radiologic assessments and evaluation by a pulmonary specialist as in case of Grade 2.</li> <li>Treatment with high dose corticosteroids until resolution of symptoms may be indicated</li> <li>Bronchoscopy with lavage and/or biopsy when clinically feasible should be performed.</li> <li>The pneumonitis event must be followed until resolution.</li> </ul>	Grade 3
Permanently discontinue MIRV	• Same as grade 3	Grade 4
• Fellin		

### STRO-002-GM1 safety

BGOG

**KU LEUVEN** 

Most common TEAEs (>25%), n (%)	4.3 mg/kg (n=23)		5.2 mg/kg (n=21)		Total (N=44)	
	Any Grade	G3+	Any Grade	G3+	Any Grade	G3+
Patients reporting ≥1 event	23 (100)	18 (78.3)	21 (100)	20 (95.2)	44 (100)	38 (86.4)
Haematological						
Neutropenia*	17 (73.9)	15 (65.2)	18 (85.7)	16 (76.2)	35 (79.5)	31 (70.5)
Febrile neutropenia	1 (4.3)	1 (4.3)	1 (4.8)	1 (4.8)	2 (4.5)	2 (4.5)
Platelet count decreased	11 (47.8)	1 (4.3)	10 (47.6)	2 (9.5)	21 (47.7)	3 (6.8)
Anaemia	8 (34.8)	1 (4.3)	12 (57.1)	5 (23.8)	20 (45.5)	6 (13.6)
whate blood cell count decreased	11 (47.8)	6 (26.1)	4 (19)	4 (19)	15 (34.1)	10 (22.7)
Non-haematological						
Nausea	17 (73.9)	0	16 (76.2)	0	33 (75)	0
Fatigue	16 (69.6)	3 (13)	11 (52.4)	1 (4.8)	27 (61.4)	4 (9.1)
Arthralgia	14 (60.9)	6 (26.1)	12 (57.1)	2 (9.5)	26 (59.1)	8 (18.2)
Constipation	9 (39.1)	0	13 (61.9)	1 (4.8)	22 (50)	1 (2.3)
Neuropathy <sup>+</sup>	11 (47.8)	1 (4.3)	8 (38.1)	0	19 (43.2)	1 (2.3)
Abdominal pain	8 (34.8)	0	10 (47.6)	0	18 (40.9)	0
Decreased appetite	8 (34.8)	0	10 (47.6)	0	18 (40.9)	0
Diarrhoea	8 (34.8)	2 (8.7)	7 (33.3)	1 (4.8)	15 (34.1)	3 (6.8)
Vomiting	7 (30.4)	0	8 (38.1)	2 (9.5)	15 (34.1)	2 (4.5)
Pyrexia	8 (34.8)	0	7 (33.3)	1 (4.8)	15 (34.1)	1 (2.3)
AST increased	8 (34.8)	0	7 (33.3)	0	15 (34.1)	0
ALT increased	8 (34.8)	0	6 (28.6)	0	14 (31.8)	0
Myalgia	6 (26.1)	0	7 (33.3)	0	13 (29.5)	0
Headache	9 (39.1)	0	3 (14.3)	0	12 (27.3)	0



## Farletuzumab ecteribulin (FZEC; MORAb-202)

• Study 101: dose expansion phase safety data

#### Most common TEAEs (≥10% in either cohort)

LGOG

Parameter, n (%)	Cohort 1: FZE (n =	EC 0.9 mg/kg 24)	Cohort 2: FZEC 1.2 mg/kg (n = 21)	
	Any grade	Grade 3/4	Any grade	Grade 3/4
Any TEAEs	24 (100)	8 (33.3)	20 (95.2)	6 (28.6)
Any treatment-related TEAEs	22 (91.7)	2 (8.3)	18 (85.7)	4 (19.0)
ILD / pneumonitis	9 (37.5)	0	14 (66.7)	1 (4.8)
Pyrexia	8 (33.3)	0	9 (42.9)	0
Nausea	6 (25.0)	0	7 (33.3)	0
Nasopharyngitis	5 (20.8)	0	1 (4.8)	0
Increased ALT level	5 (20.8)	0	4 (19.0)	0
Increased γ-glutamyl transferase	5 (20.8)	1 (4.2)	1 (4.2)	0
Malaise	4 (16.7)	0	6 (28.6)	0
Vomiting	4 (16.7)	0	1 (4.8)	0
Increased AST level	4 (16.7)	0	4 (19.0)	0
Headache	3 (12.5)	0	10 (47.6)	0
Diarrhoea	3 (12.5)	0	5 (23.8)	0
Constipation	3 (12.5)	0	3 (14.3)	0
Anaemia	3 (12.5)	1 (4.2)	4 (19.0)	1 (4.8)
Decreased appetite	3 (12.5)	1 (4.2)	2 (9.5)	0
Cataract	2 (8.3)	1 (4.2)	3 (14.3)	1 (4.8)
Arthralgia	2 (8.3)	0	3 (14.3)	0
Dysgeusia	2 (8.3)	0	3 (14.3)	0
Stomatitis	1 (4.2)	0	3 (14.3)	0
Decreased white blood cell count	0	0	4 (19.0)	0
Peripheral sensory neuropathy	O xcolegical Oncolegical Trial groups	0	3 (14.3)	0

#### **Respiratory AEs**


Parameter, n (%)	Cohort 1: FZEC 0.9 mg/kg (n = 24)	Cohort 2: FZEC 1.2 mg/kg (n = 21)
Any ILD / pneumonitis event	9 (37.5)	14 (66.7)
Severity:		
Grade 1	8 (33.3)	6 (28.6)
Grade 2	1 (4.2)	7 (33.3)
Grade 3	0	1 (4.8)
Grade 4	0	0
Grade 5	0	0
Serious event of ILD / pneumonitis / dyspnea	2 (8.3)	3 (14.3)
ILD / pneumonitis event leading to FZEC:		
Discontinuation	1 (4.2)	5 (23.8)
Dose reduction	5 (20.8)	9 (42.9)
Dose interruption	1 (4.2)	4 (19.0)

Tables adapted from Nishio S, et al.<sup>1</sup>

Data cutoff date: October 31, 2021. AE, adverse event; FZEC, farletuzumab ecteribulin; ILD, interstitial lung disease; TEAE, treatment emergent adverse event. 1. Nishio S, et al. American Society of Clinical Oncology (ASCO) Annual Meeting. 2022; Abs 5513 and poster.

### **Rinatabart sesutecan: Phase 1/2 study safety data**

- In dose escalation at 100 120 mg/m<sup>2</sup> (n = 35):
  - Most common any grade TEAEs were cytopenias<sup>a</sup> (34.3% 60.0%)
     No signals of ocular toxicities, neuropathy, or ILD were observed
- OC dose expansion at 100 120 mg/m<sup>2</sup>:



### **Summary**

- Compared to chemotherapy, MIRV is associated with lower rates of:
  - Grade 3 or greater TEAEs (42% vs 54%)
  - Serious adverse events (24% vs 33%)
  - TEAEs leading to discontinuation of study drug (9% vs 16%)
- Most frequent adverse events were ocular
  - Predominantly Grade 1-2
  - Mitigation strategy and ophthalmologic follow-up were mandatory
  - Mostly reversible in nature



### **Summary**

- Non-ocular adverse events are
  - **GI**: nausea, diarrhoea and fatigue grade 1-2
  - Peripheral neuropathy:
    - incidence was lower than paclitaxel (22% vs 29%)
    - mostly grade 1-2
  - Haematological toxicity
    - less than 12% (mostly grade 1-2)
  - Be aware of **ILD/pneumonitis** although not the most frequent AE



### **Summary**

- ADCs have their own unique toxicities/adverse events (mainly off-target)
- Get to know your ADC!

- The following measures are key!
  - Supportive measures
  - Interruptions
  - Reductions
  - Discontinuations



# Questions?

